| Patients with MMN should initially be treated with ivIg therapy. | 2 A |
| Note: Because this indication is not licensed, the application would be done in the ‘off-label use’. The legal issues involved in this are pointed out in section 0.4. A scientific account on this application of ivIg is being prepared by the circle of experts ‘Off-Label Use’1* in neurology/psychiatry located at the BfArM (www.bfarm.de).) |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.